NASDAQ · Biotechnology · USD

Turn Therapeutics Inc. (TTRX) Stock Analysis

Turn Therapeutics Inc. (TTRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TTRX

$9.80

−$0.27 (−2.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TTRX with… →

TTRX Key Statistics

As of Sep 4, 2026

Trading

Open: $9.98
Previous Close: $10.07
Day's Range: 9.70–10.50
52-Week Range: 2.57–26.50
Volume: 70.60K

Valuation

Market Cap: $297.60M
P/E Ratio: unprofitable
EPS (ttm): −0.28

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$1.77M
Profit margin: 0.00%
Shares Outstanding: 30.37M

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 77.62K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TTRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+148.73%
2025 (partial year)	−43.71%

As of September 4, 2026.

TTRX Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2024	$0.00	−$1.77M	—
2023	$0.00	−$2.29M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2024	$0.00	—	−$1.80M	−$1.77M	—
2023	$0.00	—	−$2.31M	−$2.29M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2024.

TTRX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	TTRX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Turn Therapeutics Inc. (TTRX) is capitalised at $297.60M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

The 52-week range on file runs from $2.57 to $26.50. The most recent close on file for TTRX is $9.80, dated September 4, 2026. That is −$0.27 (−2.68%) against the previous close. The latest close sits 281.32% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $0.00. The same year closed with a net loss of $1.77M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.28.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on October 8, 2025, and the total return since then is +40.00%.

Growth & Income

No dividend is on file for TTRX.

So far in 2026 the price is +148.73%.

Peer Comparison

Turn Therapeutics Inc. (TTRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Turn Therapeutics Inc.	TTRX	$297.60M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Turn Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Turn Therapeutics Inc.

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.

Visit website →